205 related articles for article (PubMed ID: 25888148)
1. Recent advances in cystic fibrosis.
Milla CE; Moss RB
Curr Opin Pediatr; 2015 Jun; 27(3):317-24. PubMed ID: 25888148
[TBL] [Abstract][Full Text] [Related]
2. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
Ong T; Ramsey BW
Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis in the era of genomic medicine.
Milla CE
Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683
[TBL] [Abstract][Full Text] [Related]
4. Update on new pulmonary therapies.
Retsch-Bogart GZ
Curr Opin Pulm Med; 2009 Nov; 15(6):604-10. PubMed ID: 19696677
[TBL] [Abstract][Full Text] [Related]
5. Lung clearance index response in patients with CF with class III CFTR mutations.
Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
[No Abstract] [Full Text] [Related]
6. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
7. CFTR: cystic fibrosis and beyond.
Mall MA; Hartl D
Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
[TBL] [Abstract][Full Text] [Related]
8. [New concepts of pathophysiology and therapy in cystic fibrosis].
Hirche TO; Loitsch S; Smaczny C; Wagner TO
Pneumologie; 2005 Nov; 59(11):811-8. PubMed ID: 16385442
[TBL] [Abstract][Full Text] [Related]
9. Remarkable progress toward new treatments for cystic fibrosis.
Eldredge LC; Ramsey BW
Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
[No Abstract] [Full Text] [Related]
10. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
Tarran R; Donaldson S; Boucher RC
Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis drug Vertex's latest triumph.
Ledford H
Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
[No Abstract] [Full Text] [Related]
12. Advances in cystic fibrosis therapies.
Rowe SM; Clancy JP
Curr Opin Pediatr; 2006 Dec; 18(6):604-13. PubMed ID: 17099358
[TBL] [Abstract][Full Text] [Related]
13. Highlights of the North American Cystic Fibrosis Conference 2011.
Pabary R; Thursfield R; Davies JC
J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S9-13. PubMed ID: 22688370
[No Abstract] [Full Text] [Related]
14. Developmental paradigm for early features of cystic fibrosis.
Larson JE; Cohen JC
Pediatr Pulmonol; 2005 Nov; 40(5):371-7. PubMed ID: 15830387
[TBL] [Abstract][Full Text] [Related]
15. Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.
Guglani L
Indian J Pediatr; 2015 Aug; 82(8):727-36. PubMed ID: 26077199
[TBL] [Abstract][Full Text] [Related]
16. Failure of local defense mechanisms in cystic fibrosis.
Proesmans M; De Boeck K
Acta Otorhinolaryngol Belg; 2000; 54(3):367-72. PubMed ID: 11082773
[TBL] [Abstract][Full Text] [Related]
17. The epithelium as a target for therapy in cystic fibrosis.
Thelin WR; Boucher RC
Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and management of pulmonary infections in cystic fibrosis.
Gibson RL; Burns JL; Ramsey BW
Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
[TBL] [Abstract][Full Text] [Related]
19. Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future.
Pettit RS; Johnson CE
Ann Pharmacother; 2011 Jan; 45(1):49-59. PubMed ID: 21156814
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
Boucher RC
Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
